Alzheimer Disease Detection Empowered with Transfer Learning

Taher M Ghazal,Munir Ahmad,Ghassan F Issa,Sagheer Abbas,M A Khan,Muhammad Adnan Khan,Mohammad Kamrul Hasan,Sundus Munir,Syeda Binish Zahra

doi:10.32604/cmc.2022.020866

Abstract

Alzheimer's disease is a severe neuron disease that damages brain cells which leads to permanent loss of memory also called dementia. Many people die due to this disease every year because this is not curable but early detection of this disease can help restrain the spread. Alzheimer's is most common in elderly people in the age bracket of 65 and above. An automated system is required for early detection of disease that can detect and classify the disease into multiple Alzheimer classes. Deep learning and machine learning techniques are used to solve many medical problems like this. The proposed system Alzheimer Disease detection utilizes transfer learning on Multi-class classification using brain Medical resonance imagining (MRI) working to classify the images in four stages, Mild demented (MD), Moderate demented (MOD), Non-demented (ND), Very mild demented (VMD). Simulation results have shown that the proposed system model gives 91.70% accuracy. It also observed that the proposed system gives more accurate results as compared to previous approaches.

Highlights

Alzheimer’s disease (AD) is a disease that’s caused due to the damage of memory cells permanently, most commonly referred to as dementia
The proposed system model was developed by using Pre-trained AlexNet for the detection of AD at early stages
The proposed (ADDTLA) model is further divided into training and validation phases

Summary

Introduction

Alzheimer’s disease (AD) is a disease that’s caused due to the damage of memory cells permanently, most commonly referred to as dementia It causes the death of nerve cells and loss of tissues throughout the brain, which results in memory loss. CMC, 2022, vol., no.3 improper medication that has been specified [2] If it is diagnosed at an early stage, it can improve the patient’s life with treatment. A large number of people suffer from this disease every year, according to a recent estimate, one in 85 people will be suffering from AD by 2050 [4] This disease is ranked as the world’s 2nd most severe neurological disorder, dementia symptoms develop in approximately 60%–80% of the population who are diagnosed with Alzheimer’s disease. A clinical dementia rating (CDR) scale is used because of its simplistic nature for collaboration between medical professionals and families [5]

Methods

Results

Conclusion